Fig. 5.

MB, MPA and POS inhibit SARS-CoV-2 infection of nasal HAEEC. Antiviral effects of drug treatments represented as means ​± ​SEM of two independent replicates. Baseline levels represent the apical means ​± ​SEM of virus titer from the DMSO control sample at 1d pi. The same DMSO control was used for the pre- and post-exposure treatments. A) Nasal HAEEC grown at ALI were inoculated apically with 1000 FFU of SARS-CoV2 Wuhan (day 0), and treated with drugs in the basolateral medium in a pre-infection regimen, starting at 2h prior to virus inoculation (left) or in a post-infection regimen starting at 1 ​d pi (right). MB and MPA were administrated daily until day 3 ​at 10 ​μM or until day 6 ​at 1 ​μM. B) POS (5 and 20 ​μM) was administrated daily until day 8. Remdesivir (10 ​μM) and DMSO served respectively as positive and negative drug treatment control and were administrated daily until day 8. SARS-CoV-2 released to the apical side was collected daily by apical washing and quantified by virus TCID₅₀ titration.